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level simulation considering a cohort of 1.000.000 individuals of 60 years of age 
in a time horizon of 5 years, assuming a retirement age of 65. PCV effectiveness 
was extrapolated from infant results. Absence days due to health events were 
retrieved from national labor legislations. Average wage was retrieved from the 
Brazilian Institute for Geography and Statistics (IBGE) 2012 data and productivity 
was estimated from the indicator ‘revenue generated by the employee’, from a 
market research developed by Exame magazine in 2012 using IBGE and the 
Brazilian Central Bank data. The base case considered a large corporation in 
Brazil with approximately 4000 eligible individuals. Values were expressed in 
2012 USD. RESULTS: Independent campaign with PPV23 and PCV13 vaccination 
plus free campaign totaled US$40.62 and US$61.40 per employee respectively. 
Productivity loss due to sick leave and death was US$709.61 and US$640.80 for 
PPV23 and PCV13 per employee, respectively. Considering all evaluated costs per 
employee and the number of eligible individuals, PPV23 and PCV13 totaled 
US$3,000,901.79 and US$2.808.787,58, respectively, representing US$192,114.21 of 
total savings for PCV13 vaccination when compared to PPV23. CONCLUSIONS: 
PCV13 vaccination with free campaign is estimated to save costs to employers, 
when compared to developing an independent campaign, mainly driven by 
productivity loss due to sick leave and death, which represented 112,07% of the 
total investment in a time horizon of 5 years.  
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OBJECTIVES: HAV is the most common cause of viral hepatitis in Latin America. 
We aimed to assess the cost-effectiveness of universal HAV immunization in 
Mexico. METHODS: A published dynamic transmission model was used to 
project the annual frequency of symptomatic HAV infections (sHAV) for a 25-
years timeframe. A decision tree allowed estimating the health and economic 
burden associated with sHAV for either a one-dose or a two-dose scheme in 
toddlers as well as without vaccination. A 80% vaccine coverage was used by 
weighting the data reported for 70% and 90% scenarios. Analysis was conducted 
from the perspective of the public health care institutions. Direct medical costs 
comprising both acquisition and administration of HAV vaccine besides medical 
care of sHAV cases were assessed. Costs are expressed in 2012 Mexican pesos 
(MXN). An average disutility value of 0.019 was imputed to each sHAV case. 
Exhaustive sensitivity analyses were performed. RESULTS: Without vaccination 
15,178,489 sHAV are expected for the period 2012-2036. Direct medical costs of 
$10,447 million MXN will be imposed by these cases, which will also entail a loss 
of 242,943 quality-adjusted life years (QALY). The one-dose scheme led to 36% 
and 32% reductions in the frequency of sHAV and QALY lost respectively, 
whereas for the two-dose scheme these reductions were of 54% and 45%. 
Incremental cost-utility ratios of $22,079 and $42,843 MXN were calculated for 
one-dose and two-dose schemes, respectively. The cost per additional QALY 
gained with two-dose versus one-dose scheme was $94,557 MXN. All these 
figures are less than the GDP per capita in Mexico ($136,384 MXN). Model was 
robust; one-dose and two-dose schemes were preferred in 42 and 57% of the 
second-order Monte-Carlo simulations. CONCLUSIONS: These results suggest 
that universal vaccination of toddlers against HAV in Mexico (either with a 1-
dose or a 2-doses scheme) is a highly cost-effective intervention.  
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OBJECTIVES: External ventricular drain (EVD) catheters provide standard means 
of monitoring intracranial pressure and alleviating excess cerebrospinal fluid 
(CSF). Up to 27% of patients with EVD catheters develop an infection. Antibiotic-
impregnated catheters (AICs) were used to reduce EVD catheter-related 
infections and the associated complications. The study was conducted to 
determine whether adopting AICs as a strategy to reduce EVD catheter-related 
infections in Canadian hospitals would be cost-effective. METHODS: Clinical and 
economic data was obtained from peer-reviewed literature along with case-
costing data from a large Canadian hospital. One and two way sensitivity 
analyses were conducted on clinical and economic parameters to ensure 
robustness. The model outcomes reflect that of a hospital with 250 catheter 
insertions per year. The data used to demonstrate a reduction in infection rate 
resulting from the use of AICs comes from a prospective, randomized, controlled 
trial. The cost of treating one episode of infection was calculated by using 
associated additional length of stay and its cost. Information regarding the cost 
was obtained from a large Canadian hospital. RESULTS: Adopting AICs as EVD 
catheters could reduce the incidence of catheter-related infection from 9.4% to 
1.3%. Using a hypothetical hospital that completes a total of 250 EVD catheter 
insertions per year would experience 24 infections using conventional catheters. 
Adopting AICs would reduce the number of infections to 4, for a total reduction 
of 20 infections. Patients that acquire infection during EVD catheter insertion 
spend an average of 8.5 additional days in hospital. The model establishes that 
the use of AICs has the potential to provide the hospital with a yearly net cost 
savings of $250,599 despite the added costs of AICs. CONCLUSIONS: AICs are a 
cost-effective strategy that can be used to prevent catheter-related CSF infection 
for EVD catheter insertion in Canadian hospitals.  
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OBJECTIVES: Current U.S. Department of Health and Human Services (DHHS) 
HIV treatment guidelines recommend that HIV patients initiate first-line 
antiretroviral therapy (ART) with one of four “preferred” regimens: 
efavirenz/tenofovir/emtricitabine (EFV/TDF/FTC), ritonavir-boosted atazanavir + 
tenofovir/emtricitabine (ATV/r+TDF/FTC), ritonavir-boosted darunavir + 
tenofovir/emtricitabine (DRV/r+TDF/FTC), or raltegravir + tenofovir/emtricitabine 
(RAL+TDF/FTC). While the clinical value of these regimens is well-supported, 
there are limited data on their relative economic value. This study compared 
health care expenditures between the four “preferred” ART regimens. METHODS: 
Retrospective study using Medicaid administrative health care claims from 15 
states. Subjects were HIV patients aged 18-64 years who were enrolled in 
Medicaid and initiated, between January 1, 2007 and September 30, 2011, a first-
line ART regimen “preferred” under U.S. DHHS HIV treatment guidelines 
published in March 2012. Patients were classified by ART regimen and were 
required to be continuously enrolled for 6 months before and ≥3 months 
following ART initiation. Follow up lasted from ART initiation until a ≥30 day gap 
in initiated ART, introduction of a new ART medication, or disenrollment. Per-
patient-per-month (PPPM) total mean health care expenditures during follow up 
were evaluated using log-linear regressions. Log-expenditures were 
retransformed via ‘smearing.’ Inference was based on recycled prediction with 
500 bootstrap repetitions. RESULTS: Sample included 1,979 patients initiating 
EFV/TDF/FTC (n=1,259), ATV/r+TDF/FTC (n=498), DRV/r+TDF/FTC (n=143), or 
RAL+TDF/FTC (n=79); mean age by regimen ranged from 40.1 to 42.1 years and 
proportion male from 44.1% to 55.4%. PPPM total mean health care expenditures 
for EFV/TDF/FTC patients were $3,476. In comparison, PPPM total mean health 
care expenditures were significantly higher for DRV/r+TDF/FTC patients (by 
$2,155, 95% CI =$1,364 to $3,074, p<0.01), ATV/r+TDF/FTC patients (by $1,379, 95% 
CI=$951 to $1,971, p<0.01) and RAL+TDF/FTC patients (by $1,479, 95% CI=$544 to -
$2,526, p<0.01) than for EFV/TDF/FTC patients. CONCLUSIONS: This study found 
significant differences in health care expenditures between HIV patients 
initiating different ART regimens “preferred” under current U.S. treatment 
guidelines.  
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OBJECTIVES: Shunts provide standard means of monitoring intracranial pressure 
and alleviating raised cerebrospinal fluid (CSF). Up to 15% of patients with shunts 
develop an infection. Antibiotic-impregnated catheters (AICs) were used with the 
goal to reduce shunt-related CSF infections and the associated complications. 
The study was conducted to determine whether adopting AICs as a strategy to 
reduce shunt infections in Canadian hospitals would be cost-effective. 
METHODS: Clinical and economic data was obtained from peer-reviewed 
literature along with case-costing data from a large Canadian hospital. One and 
two way sensitivity analyses were conducted on clinical and economic 
parameters. The model outcomes reflect that of a hospital with 250 shunt 
implantations per year. The clinical data used to demonstrate a reduction in 
shunt infections resulting from the use of AICs comes from a 2011 meta-analysis 
(Klimo et al., 2011) as well as from the outcomes of the Canadian Nosocomial 
Infection Surveillance Program. Information regarding the cost of treating an 
infected patient was obtained from a large Canadian hospital. RESULTS: 
Adopting AICs in shunt implantations could result in a relative risk reduction of 
50% in shunt-related CSF infections. Using a hypothetical hospital that 
completes a total of 250 shunt implantations per year would experience 16 shunt 
infections using conventional catheters. Adopting AICs would reduce the 
number of infections to 8, for a total reduction of 8 shunt infections. The model 
establishes that the use of AICs has the potential to provide the hospital with a 
yearly net cost savings. Taking into account the catheter replacement costs 
associated with shunt infections, the hospital would still achieve a cost savings 
of $509,632 per year despite the added upfront costs of AICs. CONCLUSIONS: 
AICs are a cost-effective strategy that can be used to prevent shunt-related CSF 
infection after shunt implantation in Canadian hospitals.  
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OBJECTIVES: To examine whether the average direct medical costs paid for adult 
vaccination differed by the vaccination setting. METHODS: An observational 
retrospective study using 2010 MarketScan® Commercial Claims and Encounters, 
and Medicare Supplemental databases. Adults receiving ZOSTAVAX® (herpes 
zoster or shingles vaccine), PNEUMOVAX® 23 (pneumococcal vaccine), or 
influenza vaccines were identified using CPT and NDC codes from medical and 
pharmacy claims files, respectively. The vaccination costs included the health 
plan and enrollee paid amounts for the product, vaccine administration, and 
where applicable, the visit. The mean (SD) vaccination costs paid per vaccine 
